ACAT1 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human Jurkat T-lymphocyte cell line, engineered to disrupt the ACAT1 gene. This polyclonal pool provides a loss-of-function model for studying mitochondrial acetyl-CoA acetyltransferase 1, which catalyzes the reversible conversion of two acetyl-CoA molecules to acetoacetyl-CoA in ketogenesis and isoleucine catabolism. The targeted gene disruption is achieved through CRISPR/Cas9-mediated editing, resulting in a heterogeneous cell population suitable for investigations into ACAT1-dependent metabolic pathways without clonal selection artifacts. Researchers can utilize this product to explore the consequences of ACAT1 ablation on ketone body metabolism, acetyl-CoA homeostasis, and energy regulation within an immune cell context.
The host Jurkat cell line originates from the peripheral blood of a 14-year-old male with acute T-cell leukemia and is widely employed as a model for T-cell signaling, apoptosis, and cytokine production. These suspension cells exhibit key features of T lymphocytes, including T-cell receptor (TCR)?Cmediated activation cascades and robust proliferative capacity, making them ideal for studying immune defense mechanisms. Jurkat cells have been extensively characterized in signal transduction research, particularly for pathways involving NFAT, NF-??B, and MAP kinases. Their malignant background also renders them suitable for cancer metabolism studies, offering a platform to interrogate metabolic adaptations in leukemic T cells.
ACAT1 encodes a mitochondrial matrix enzyme that is central to ketone body synthesis and the degradation of isoleucine. Mechanistically, ACAT1 condenses two acetyl-CoA units to form acetoacetyl-CoA, which can be further processed by HMGCS2 and HMGCL to generate acetoacetate and ??-hydroxybutyrate, or enter the mevalonate pathway. Upstream regulation involves PPAR??-dependent transcription, SIRT3-mediated deacetylation, and insulin/glucagon signaling, placing ACAT1 at a metabolic hub responsive to nutrient status. Downstream, ACAT1 activity influences levels of acetoacetyl-CoA, acetyl-CoA, and ketone bodies. It interacts with HMGCS2 and SIRT3, and operates within a network comprising HMGCL, BDH1, and OXCT1, underscoring its integration into mitochondrial fuel partitioning and redox balance.
In Jurkat T cells, ACAT1 knockout perturbs the normal coupling between ketogenesis and acetyl-CoA metabolism, potentially altering the bioenergetic landscape during T-cell activation and proliferation. Given that activated T cells undergo metabolic reprogramming toward glycolysis and glutaminolysis, loss of ACAT1 may shift acetyl-CoA utilization, impacting fatty acid oxidation, histone acetylation, and cytokine production. This model enables researchers to dissect how mitochondrial acetyl-CoA flux influences T-cell effector functions, apoptosis sensitivity, and survival under metabolic stress. It also provides a tool to examine the interplay between ketone body metabolism and immune cell signaling, which is relevant to tumor microenvironment adaptations and autoimmune conditions.
Applications of these ACAT1 knockout Jurkat cells include cancer metabolism research, where they facilitate the study of metabolic vulnerabilities in leukemia; ketone body metabolism studies using ketone body production assays and acetyl-CoA measurements; and T-cell activation assays coupled with metabolic flux analysis to assess reprogramming upon TCR stimulation. Further uses involve drug screening for ??-ketothiolase deficiency and metabolic disorders, proliferation and apoptosis assays, and validation via Western blotting or RT-qPCR for ACAT1 disruption. For technical inquiries or custom requests, please contact Ascent Research.
